| Name | Title | Contact Details |
|---|
MiraMed Global Services stands as the premier global provider of business process outsourcing solutions to healthcare organizations nationwide. MiraMed partners with hospitals, health networks, physician practices and related industry service organizations to provide a broad portfolio of customizable solutions, uncover and capitalize on hidden financial opportunities, improve productivity and ultimately increase profits. The key to MiraMed`s success is its unique business model that has evolved over the last twenty-five years. Under this model, MiraMed pairs healthcare industry experts with world-class processes, infrastructure and technology to deliver meaningful and measurable results. This proprietary model enables sustainable change by delivering a complete, customizable "end-to-end" solution devised to meet a client`s own unique financial and organizational needs.
Continuing Ed Courses is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Floyd Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Floyd Medical Center is based in Rome, GA. You can find more information on Floyd Medical Center at www.floydmed.org
MSPCA is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Jamaica Plain, MA. To find more information about MSPCA, please visit www.mspca.org
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.